{
  "id": 18223134,
  "title": "Cathie Wood’s ARK sells SpaceX stock, buys Nurix Therapeutics",
  "url": "https://urgent.news/2026/11/05/cathie-woods-ark-sells-spacex-stock-buys-nurix-therapeutics",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-05T01:14:04.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/cathie-woods-ark-sells-spacex-stock-buys-nurix-therapeutics-93CH-5001959"
  },
  "original_language": "en",
  "account": "On November 4th, 2026, Argo Investments Management, led by Cathie Wood, reported notable changes in their ETF holdings. Significant divestments included the sale of 348,406 shares of SpaceX (SPCX) across ARKK, ARKQ, and ARKW ETFs, amounting to $49,233,251. Conversely, the firm made a substantial purchase of 350,410 shares of Nurix Therapeutics, Inc. (NRIX) through the ARKG ETF, totaling $9,047,586. This shift signifies ARK's expanding interest in the biotech sector, especially companies focused on therapeutic development. Furthermore, ARK divested 46,164 shares of Alphabet Inc. (GOOG) across ARKK and ARKQ ETFs, totaling $12,846,056, continuing their trend of reducing investments in tech companies. Additionally, the firm sold 8,551 shares of Eli Lilly and Company (LLY) via ARKK ETF, valued at $12,051,608, aligning with their pattern of divesting pharmaceutical companies. On the buying side, ARK amassed 12,943 shares of Twist Bioscience Corporation (TWST) through ARKK ETF, with a total value of $1,815,902, reflecting their interest in synthetic biology firms. The company also raised its position in Pacific Biosciences of California, Inc. (PACB) by acquiring 73,281 shares across ARKK and ARKG ETFs for $178,805, continuing their accumulation strategy. Notable trades also involved the sale of 38,3022 shares of Personalis, Inc. (PSNL) through ARKG ETF, totaling $6,032,596, and the purchase of 25,758 shares of GeneDx Holdings Corp. (WGS) through ARKG ETF, valued at $1,768,029. These moves demonstrate ARK's adaptable investment strategy, balancing the sale of shares from larger tech and pharmaceutical firms with investments in emerging biotech and innovative technology companies. This report was AI-generated and reviewed by an editor.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}